284 related articles for article (PubMed ID: 16303936)
1. Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjögren's syndrome patients.
Aragona P; Bucolo C; Spinella R; Giuffrida S; Ferreri G
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4474-9. PubMed ID: 16303936
[TBL] [Abstract][Full Text] [Related]
2. Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome.
Aragona P; Rania L; Roszkowska AM; Spinella R; Postorino E; Puzzolo D; Micali A
Acta Ophthalmol; 2013 Sep; 91(6):e437-44. PubMed ID: 23617248
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome.
Aragona P; Di Pietro R; Spinella R; Mobrici M
Br J Ophthalmol; 2006 Feb; 90(2):166-70. PubMed ID: 16424527
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction.
Pinna A; Piccinini P; Carta F
Cornea; 2007 Apr; 26(3):260-4. PubMed ID: 17413949
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
[TBL] [Abstract][Full Text] [Related]
6. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
[TBL] [Abstract][Full Text] [Related]
7. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome.
Yoon KC; Jeong IY; Park YG; Yang SY
Cornea; 2007 May; 26(4):431-7. PubMed ID: 17457192
[TBL] [Abstract][Full Text] [Related]
9. Correlation between Tear Osmolarity and Other Ocular Surface Parameters in Primary Sjögren's Syndrome.
Kim M; Kim HS; Na KS
Korean J Ophthalmol; 2017 Feb; 31(1):25-31. PubMed ID: 28243020
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
11. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome.
Walters MT; Rubin CE; Keightley SJ; Ward CD; Cawley MI
Scand J Rheumatol Suppl; 1986; 61():253-8. PubMed ID: 3296153
[TBL] [Abstract][Full Text] [Related]
13. Effects of the topical treatment with NSAIDs on corneal sensitivity and ocular surface of Sjögren's syndrome patients.
Aragona P; Stilo A; Ferreri F; Mobrici M
Eye (Lond); 2005 May; 19(5):535-9. PubMed ID: 15184937
[TBL] [Abstract][Full Text] [Related]
14. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
[TBL] [Abstract][Full Text] [Related]
15. [The evaluation of chosen cytokines in induction of ocular changes in Sjögren's syndrome of dry eye].
Zywalewska-Górna N; Mrugacz M; Bakunowicz-Lazarczyk A
Klin Oczna; 2007; 109(10-12):435-7. PubMed ID: 18488390
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic significance of Fourier-domain optical coherence tomography in Sjögren syndrome, aqueous tear deficiency and lipid tear deficiency patients.
Qiu X; Gong L; Lu Y; Jin H; Robitaille M
Acta Ophthalmol; 2012 Aug; 90(5):e359-66. PubMed ID: 22568661
[TBL] [Abstract][Full Text] [Related]
17. Tear lipocalin and lysozyme in Sjögren and non-Sjögren dry eye.
Caffery B; Joyce E; Boone A; Slomovic A; Simpson T; Jones L; Senchyna M
Optom Vis Sci; 2008 Aug; 85(8):661-7. PubMed ID: 18677232
[TBL] [Abstract][Full Text] [Related]
18. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye.
Kokke KH; Morris JA; Lawrenson JG
Cont Lens Anterior Eye; 2008 Jun; 31(3):141-6; quiz 170. PubMed ID: 18313350
[TBL] [Abstract][Full Text] [Related]
19. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
Fox RI; Dixon R; Guarrasi V; Krubel S
Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
[TBL] [Abstract][Full Text] [Related]
20. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye.
Wojtowicz JC; Butovich I; Uchiyama E; Aronowicz J; Agee S; McCulley JP
Cornea; 2011 Mar; 30(3):308-14. PubMed ID: 21045648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
